Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) is a publicly traded Healthcare sector company. As of November 5, 2026, OBIO trades at $5.02 with a market cap of $360.63M and a P/E ratio of -5.24. OBIO moved -6.25% today. Year to date, OBIO is +32.43%; over the trailing twelve months it is +43.24%. Its 52-week range spans $2.20 to $6.50. Analyst consensus is strong buy with an average price target of $11.60. Rallies surfaces OBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Orchestra BioMed launches public offering of common stock: Orchestra BioMed launched an underwritten public offering of common stock, with all shares being offered by the company. Net proceeds will support AVIM Therapy and Virtue SAB programs, including pivotal trials, as well as other development and general corporate purposes.
| Metric | Value |
|---|---|
| Price | $5.02 |
| Market Cap | $360.63M |
| P/E Ratio | -5.24 |
| EPS | $-1.11 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.50 |
| 52-Week Low | $2.20 |
| Volume | 187.70K |
| Avg Volume | 0 |
| Revenue (TTM) | $33.48M |
| Net Income | $-52.70M |
| Gross Margin | 99.43% |
5 analysts cover OBIO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.60.